Objective: This was a feasibility study to determine if pregnant women with type I diabetes managed with liberal target glucose values will have a decreased frequency of hypoglycemia with no differences in adverse outcomes compared with tightly controlled subjects.
Introduction
Control of maternal glycemia is a central element of the management of all types of diabetes in pregnancy. Consensus statements 1, 2 and published guidelines 3 suggest target fasting and pre-meal glucose values of 60 to 110 mg/dl and 1 to 2 hours post-prandial targets of 120 to 155 mg/dl. Neither consensus statements nor guidelines suggest the establishment of different target values for women who have type I and type II diabetes. However, attempting 'tight' glycemic control for pregnant women who have type I diabetes is frequently accompanied by recurrent, potentially life-threatening hypoglycemia. [4] [5] [6] Maintenance of normoglycemia for all pregnant diabetic women is premised on the assumption of a causal relationship between lower maternal glucose concentrations and diminished perinatal morbidity and mortality. 7, 8 However, some data suggest that optimal pregnancy outcomes may be achieved for type I diabetic women if less rigid glycemic targets are utilized. Three studies reported a similar incidence of large for gestational age infants of type I and type II diabetic women despite significantly higher mean maternal glucose concentrations during pregnancy among the former. [9] [10] [11] One of these 11 also reported a higher perinatal mortality rate for pregnancies of the women who had type II diabetes. Our hypothesis was that compared with those attempting to maintain 'tight' glycemic control, pregnant women with type I diabetes who are managed with liberal target glucose values will have a decreased frequency of subjective and objective hypoglycemia with no differences in adverse perinatal outcomes. This was designed as a feasibility study to determine patient compliance with the requirements of this 'open-label' study design. We also intended to analyze and report any preliminary findings comparing the two groups.
Materials and methods
Pregnant women who had type I diabetes and who presented for prenatal care before their thirteenth gestational week were recruited for the study. Identification of type I diabetes was made on clinical grounds, including the requirement for insulin to sustain life and/ or a history of abrupt onset of diabetes, diabetic ketoacidosis or both. 12 At the time of recruitment, subjects were informed of the purpose of the study, and that randomization to one of two groups would be performed only after the woman had volunteered to participate.
All women were instructed in diet, insulin administration and glucose self-monitoring. Diet caloric content was based on the percent of ideal pre-pregnancy weight. The diet was divided into 40% carbohydrates, 20% fat and 40% protein, and subdivided into three meals and frequent small snacks. For those women using multiple injections, combinations of intermediate acting (NPH) and either regular insulin or insulin lispro (Humalog, Eli Lilly, Indianapolis, IN) were used to control maternal glycemia. Women using continuous insulin infusion (insulin pumps) were trained to adjust their basal and bolus doses of insulin lispro to achieve the glycemic control dictated by the target values for their respective group.
Participants were given a memory-based portable glucose meter with capabilities for recording events (Accu-Chek Complete Blood Glucose Monitoring System -Roche Diagnostics, Indianapolis, IN). They were requested to perform capillary plasma glucose self-monitoring seven times a day, before and 1 hour after the first bite of each meal and at bedtime. Participants were also requested to record symptoms of hypoglycemia (e.g. nervousness, tremulousness and peri-oral numbness) and to test their blood glucose when they experienced these symptoms. Initial instructions included performance under observation of glucose self-monitoring as well as testing with control solutions, the latter to be performed with every new bottle of test strips. Patients were seen every 1 to 2 weeks. Meters were downloaded to a data collection program (Camit-Pro -Roche Diagnostics) at office visits and then electronically transmitted to the central data collection site using secure software (Accutility -Roche Diagnostics, Indianapolis, IN).
Assignment to the 'rigid' or 'less rigid' groups was carried out by computer-generated block randomization. Patients were given written and verbal instructions in the daily adjustment of their insulin doses to achieve targeted glucose values for their assigned group. Those in the 'rigid' group were given fasting and pre-meal glucose targets of 60 to 90 mg/dl and 1-hour post-meal targets of 120 to 140 mg/dl. The respective target glucose values for those in the 'less rigid' group were 95 to 115 and 155 to 175 mg/dl. The latter values were derived from previous reports of glycemic thresholds for spontaneous abortions and malformations, 13 and for perinatal mortality among type I diabetic women. 10 Laboratory analyses upon entry into the study included C-peptide, thyroid-stimulating hormone, anti-glutamic acid decarboxylase (GAD) antibody, islet cell (ICA-512) autoantibodies and highly sensitive insulin antibody. Hemoglobin A1c was repeated once each trimester. All studies were performed by a central laboratory (Quest Diagnostics, San Juan Capistrano, CA). Triple marker maternal serum analyses, fetal sonographic anatomical surveys and fetal echocardiography were performed between 15 and 20 weeks. Antepartum fetal testing, timing and route of delivery were performed at the discretion of the attending obstetrician. During the intrapartum period, maternal glucose was frequently monitored and insulin administered to keep maternal glucose between 70 and 110 mg/dl.
Statistics
In our previous study, 10 the rate of hypoglycemia among pregnant type I diabetic women managed with 'tight' glycemic targets was 19%. We hypothesized that the hypoglycemia rate in the 'less rigid' group would be 5%. The detection of this magnitude of difference in hypoglycemia with a level of significance of 5% and a power of 80% would require 84 patients per group.
Body mass index was calculated by the formula BMI ¼ weight (in kilograms)/height (in meters) 2 . Maternal weight gain was calculated by the formula mean weight gain ¼ (weight at last visitÀpre-pregnancy weight-birth weight)/number of intervening weeks. Birth weight was expressed as the population-specific percentile birth weight for gestational age and gender. 14, 15 Categorical data were analyzed using Fisher's exact test and group comparisons with continuous data were based on the nonparametric Wilcoxon's rank-sum test. The level of statistical significance was set as 0.05. All analyses were performed with SAS software (Version 8.2), Cary, NC.
Ethics
Written informed consent was obtained from each subject. The conduct of this study was in conformity with the ethical standards for human experimentation established by the Declaration of Helsinki of 1975, revised in 1983. 16 This study was reviewed and approved by the Kaiser Permanente Institutional Review Board for the protection of human subjects and by the University of Toronto Research Services -Ethics Review Unit.
Results
Patients were recruited into the study from 1 April 2000 to 31 March 2003. Thirteen were randomized to the 'rigid' group and 13 to the 'less rigid' group. Among the latter, two had first trimester spontaneous abortions, one was deleted because she had participated in an earlier pregnancy and one left the study because she declined to come for appointments. Maternal baseline characteristics of active participants are summarized in Table 1 . All but one subject had evidence of either anti-islet cell, anti-insulin or anti-GAD antibodies. All but four had C-peptide levels below detectable range. No patient in either group had evidence of advanced diabetic retinopathy or nephropathy. Two patients in each group failed to bring in a 24-hour urine specimen for protein, and four from each group did not bring in a 24-hour urine collection for creatinine clearance.
Maternal glycemic measures are reported in Table 2 . Mean first trimester maternal hemoglobin A1c for women in the 'rigid' and 'less rigid' groups were drawn at 8.4 and 8.6 weeks, respectively (P ¼ 0.86). Mean maternal glucose concentrations were significantly greater in first and second trimesters among women in the 'less rigid' group. Both objective and subjective hypoglycemia were reported more frequently among women in the 'rigid' group. Subjective hypoglycemia was rarely reported above a maternal glucose concentration of 70 mg/dl. We wished to compare the incidence of hypoglycemic unawareness between the two groups at different maternal glucose concentrations. Because the number of observations differed from subject to subject, this was calculated as the percentage mean of the number of subjective hypoglycemic episodes reported per patient per defined range of maternal glucose concentration. No subjective hypoglycemia was reported by any subject in either the 'rigid' or the 'less rigid' groups accompanying any maternal glucose measure X90 mg/dl. A total of 6955 maternal glucose measures among the 'rigid' subjects and 1686 measures among the 'less rigid' subjects below 90 mg/dl were recorded. Within any given range of lower maternal blood glucose concentrations, the proportion of women who experienced subjective hypoglycemia was not significantly different among those managed with either the 'rigid' or 'less rigid' protocol (Table 3 ). Five women in the 'rigid' group and three in the 'less rigid' group used continuous subcutaneous insulin infusion (insulin pumps) during pregnancy. Similar mean glucose concentrations were found for those who used pumps and those who did not in both 'rigid' (123±7 versus 129±15 mg/dl, respectively; P ¼ 0.83) and 'less rigid' (145±10 versus 146±17 mg/dl respectively; P ¼ 0.71) groups.
Expressed as either grams or percentile birth weight for gestational age, there were no statistically significant differences in birth weights between groups. All neonates were live born singletons. The percent of neonates whose initial capillary glucose concentration fell within a hypoglycemic range was also not significantly different between groups (Table 4 ). There were no fetal or neonatal deaths. Two babies were delivered with isolated birth defects. Both defects (tricuspid dysplasia and syndactyly of the second and third toes) occurred in infants of mothers in the 'rigid' group. Respective first trimester hemoglobin A1c values were 6.0 and 6.4% for each of their mothers.
Discussion
This feasibility study was successful to the extent that patients in the 'less rigid' group achieved higher mean maternal glucose concentrations than did those in the 'rigid' group, suggesting patient compliance with the requirements of the study. There was no perinatal mortality or serious morbidity among any study patients. We feel that these findings justify a larger study modeled on the present design. Some apparent differences in study groups bear clarification. That the difference in pre-conception care and pre-pregnancy BMI between groups approached statistical significance (Table 1) is likely a function of small sample size. All measures of maternal glucose control were begun in first trimester at the time of enrollment for the study. That the direction of difference of mean maternal glucose is toward higher concentrations in the 'less rigid' group in each trimester (Table 2) suggests patient compliance with the protocol. That patient enrollment was at 6 to 7 weeks and that the first trimester hemoglobin A1c was drawn at a mean 8 to 9 weeks suggests that the latter likely reflects both pre-conception glycemic control as well as response to treatment early in the study.
Pre-gestational diabetes complicates from 1 to 3/1000 births, 17 and constitutes approximately 10% of all diabetes seen during pregnancy. 2 Although the relative incidence of types I and II diabetes during pregnancy varies with age, ethnicity and geographic locale, overall 5 to 10% of all individuals who have diabetes have type I. 18 That there may be merit in using different target glucose values for type I and type II diabetic women during pregnancy is suggested by the findings of a previous study in which identical glucose values were targeted by all pre-gestationally diabetic women. Despite greater compliance with requirements for glucose self-monitoring and daily self-adjustment of insulin, women who had type I diabetes had significantly greater mean glucose concentrations and glycemic excursions than did those who had type II diabetes. Important clinical outcomes were not significantly different between groups. However, the frequency with which hypoglycemia occurred among women who had type I diabetes was nine times that of women who had type II diabetes. 10 Defined as a glycemic concentration resulting in impaired consciousness requiring the assistance of another, severe hypoglycemia has been reported in 41 to 71% of pregnant type I diabetic women undergoing intensive insulin therapy. 5, 6, 19 Coma, seizures, vehicular accidents and maternal deaths have been attributed to hypoglycemia and hypoglycemic unawareness during these women's pregnancies. 19, 20 Recurrent hypoglycemia may have cumulative adverse effects on cognitive function. 21 Counterregulatory hormonal responses to hypoglycemia change during pregnancy. Both normoglycemic women and those who have type I diabetes have diminished peak epinephrine and glucagon responses to induced hypoglycemia during pregnancy. 22 Furthermore, during pregnancy the magnitude of the epinephrine response among type I diabetic women is significantly less than that of non-diabetic women. 22 Thus, the impaired counter-regulatory response to hypoglycemia, which is a normal concomitant of pregnancy, may be exacerbated in women who have type I diabetes.
The possibility of preservation of glucose counter-regulation 22 and of hypoglycemic awareness by raising glucose targets has been suggested previously. 23 In the present study, women who used the less rigid glycemic targets had fewer subjective and objective hypoglycemic episodes (Table 2) . However, at any given maternal glucose concentration, there were no significant differences in the frequency of hypoglycemic unawareness between women in the 'rigid' and in the 'less rigid groups (Table 3) .
A major concern in raising target maternal glucose values is the risk of increasing the incidence of adverse perinatal and/or maternal outcomes. Fetal growth and overgrowth are clinical outcomes by which the effectiveness of glycemic control of pregnancies complicated by diabetes is frequently measured. Although the differences in absolute birth weight and birth weight percentile among our patients did not achieve statistical significance, the mean birth weight of babies of mothers in the 'less rigid' group was 272 g greater than that of the babies of mothers in the 'rigid' group (Table 4 ). The absence of 24 or a weak 25 relationship between maternal glycemic measures and fetal macrosomia among infants of type I diabetic mothers has been noted previously. The suggestion has been made that among infants of women who have type I diabetes maternal glycemia may be of lesser importance as a determinant of birth weight and body composition than are determinants of growth intrinsic to the fetus. Among the latter are genetic determinants of fetal insulin secretion and sensitivity unique to infants of type I diabetic women. These, more than availability of maternal glucose, may be overriding determinants of the amount of substrate reaching fetal cells. 24 The limited number of subjects whom we were able to recruit for this study allowed the determination of only the feasibility of patient compliance with this protocol. The number of patients in this study is insufficient to draw definitive conclusions. Our data suggest the possibility that for pregnant women who have type I diabetes utilizing glucose targets higher than those conventionally recommended may decrease the incidence of clinical and chemical hypoglycemia while not increasing maternal or perinatal morbidity. We submit these data in the hope that others may be encouraged to further investigate this possibility.
